Literature DB >> 22072777

Δγ₁134.5 herpes simplex viruses encoding human cytomegalovirus IRS1 or TRS1 induce interferon regulatory factor 3 phosphorylation and an interferon-stimulated gene response.

Kevin A Cassady1, Ute Saunders, Masako Shimamura.   

Abstract

The chimeric herpes simplex viruses (HSV) are Δγ₁34.5 vectors encoding the human cytomegalovirus (HCMV) IRS1 or TRS1 genes. They are capable of late viral protein synthesis and are superior to Δγ₁34.5 HSVs in oncolytic activity. The interferon (IFN) response limits efficient HSV gene expression and replication. HCMV TRS1 and IRS1 restore one γ₁34.5 gene function: evasion of IFN-inducible protein kinase R, allowing late viral protein synthesis. Here we show that, unlike wild-type HSV, the chimeric HSV do not restore another γ₁34.5 function, the suppression of early IFN signaling mediated by IFN regulatory factor 3 (IRF3).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072777      PMCID: PMC3255867          DOI: 10.1128/JVI.05099-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein.

Authors:  J Talon; C M Horvath; R Polley; C F Basler; T Muster; P Palese; A García-Sastre
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals.

Authors:  I Mohr; D Sternberg; S Ward; D Leib; M Mulvey; Y Gluzman
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 3.  Rabies viral mechanisms to escape the IFN system: the viral protein P interferes with IRF-3, Stat1, and PML nuclear bodies.

Authors:  Mounira K Chelbi-Alix; Aurore Vidy; Jamila El Bougrini; Danielle Blondel
Journal:  J Interferon Cytokine Res       Date:  2006-05       Impact factor: 2.607

4.  HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer.

Authors:  Fabian Benencia; Maria C Courrèges; José R Conejo-García; Alisha Mohamed-Hadley; Lin Zhang; Ronald J Buckanovich; Richard Carroll; Nigel Fraser; George Coukos
Journal:  Mol Ther       Date:  2005-05-31       Impact factor: 11.454

5.  Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses.

Authors:  K Ikeda; T Ichikawa; H Wakimoto; J S Silver; T S Deisboeck; D Finkelstein; G R Harsh; D N Louis; R T Bartus; F H Hochberg; E A Chiocca
Journal:  Nat Med       Date:  1999-08       Impact factor: 53.440

6.  Triggering of TLR3 by polyI:C in human corneal epithelial cells to induce inflammatory cytokines.

Authors:  Mayumi Ueta; Junji Hamuro; Hiroshi Kiyono; Shigeru Kinoshita
Journal:  Biochem Biophys Res Commun       Date:  2005-05-27       Impact factor: 3.575

7.  Herpes simplex virus 1 infection induces the expression of proinflammatory cytokines, interferons and TLR7 in human corneal epithelial cells.

Authors:  Hui Li; Jing Zhang; Ashok Kumar; Mei Zheng; Sally S Atherton; Fu-Shin X Yu
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

8.  Toll-like receptor 3 agonist poly(I:C)-induced antiviral response in human corneal epithelial cells.

Authors:  Ashok Kumar; Jing Zhang; Fu-Shin X Yu
Journal:  Immunology       Date:  2006-01       Impact factor: 7.397

9.  Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins.

Authors:  S Andreansky; B He; J van Cott; J McGhee; J M Markert; G Y Gillespie; B Roizman; R J Whitley
Journal:  Gene Ther       Date:  1998-01       Impact factor: 5.250

Review 10.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

View more
  9 in total

1.  Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures.

Authors:  Gregory K Friedman; Marilyn C Haas; Virginia M Kelly; James M Markert; George Yancey Gillespie; Kevin A Cassady
Journal:  Transl Oncol       Date:  2012-06-01       Impact factor: 4.243

Review 2.  Gene therapy as a potential tool for treating neuroblastoma-a focused review.

Authors:  M D Kumar; A Dravid; A Kumar; D Sen
Journal:  Cancer Gene Ther       Date:  2016-04-15       Impact factor: 5.987

3.  STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells.

Authors:  Joshua D Jackson; James M Markert; Li Li; Steven L Carroll; Kevin A Cassady
Journal:  Mol Cancer Res       Date:  2016-02-16       Impact factor: 5.852

4.  Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates.

Authors:  Kevin A Cassady; David F Bauer; Justin Roth; Melissa R Chambers; Trent Shoeb; Jennifer Coleman; Mark Prichard; G Yancey Gillespie; James M Markert
Journal:  Mol Ther Oncolytics       Date:  2017-03-01       Impact factor: 7.200

5.  Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy.

Authors:  Mohammed G Ghonime; Uksha Saini; Michael C Kelly; Justin C Roth; Pin-Yi Wang; Chun-Yu Chen; Katherine Miller; Ilse Hernandez-Aguirre; Yeaseul Kim; Xiaokui Mo; Joseph R Stanek; Tim Cripe; Elaine Mardis; Kevin A Cassady
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 12.469

Review 6.  Immunotherapeutic Challenges for Pediatric Cancers.

Authors:  Brian Hutzen; Mohammed Ghonime; Joel Lee; Elaine R Mardis; Ruoning Wang; Dean A Lee; Mitchell S Cairo; Ryan D Roberts; Timothy P Cripe; Kevin A Cassady
Journal:  Mol Ther Oncolytics       Date:  2019-08-28       Impact factor: 7.200

7.  STING Restricts oHSV Replication and Spread in Resistant MPNSTs but Is Dispensable for Basal IFN-Stimulated Gene Upregulation.

Authors:  Joel M Lee; Mohammed G Ghonime; Kevin A Cassady
Journal:  Mol Ther Oncolytics       Date:  2019-09-16       Impact factor: 7.200

Review 8.  Tumor Control by Cytomegalovirus: A Door Open for Oncolytic Virotherapy?

Authors:  Georges Herbein; Zeina Nehme
Journal:  Mol Ther Oncolytics       Date:  2020-03-29       Impact factor: 7.200

Review 9.  Oncolytic HSV: Underpinnings of Tumor Susceptibility.

Authors:  Chase Kangas; Eric Krawczyk; Bin He
Journal:  Viruses       Date:  2021-07-20       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.